-
Mega Lifesciences Secures Exclusive Rights for Bio-Thera’s Bevacizumab Biosimilar in Indonesia
•
Thailand-based Mega Lifesciences (BKK: MEGA) has announced an in-licensing agreement with China-based Bio-Thera Solutions (SHA: 688177) for bevacizumab (BAT1706), a biosimilar version of Roche’s (SWX: ROG) Avastin (bevacizumab). According to the agreement, Mega Lifesciences obtains exclusive distribution and marketing rights to the product in Indonesia, while Bio-Thera will handle the…
-
Jiangsu Hengrui’s Dalpiciclib Approved for Initial Therapy in HR+, HER2- Breast Cancer
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced receiving another indication approval for its drug dalpiciclib (SHR6390). The approval is for use as an initial therapy combined with an aromatase inhibitor for patients with hormone receptor (HR) positive, human epidermal growth factor…
-
Fosun Kite’s Yescarta Gains NMPA Approval for Refractory Large B-Cell Lymphoma
•
China-based Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196; HKG: 2196) and Gilead (NASDAQ: GILD) subsidiary Kite Pharma, has announced that its product Yescarta (axicabtagene ciloleucel) has obtained marketing approval from the National Medical Products Administration (NMPA) for a new indication…
-
Sinopharm Expands Partnership with Guizhou Government to Boost Health Industry
•
China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strengthened partnership with the government of Guizhou province. This collaboration expands upon previous achievements in promoting cooperation in biomedicine, traditional Chinese medicine R&D, and the construction of grassroots public health systems. Comprehensive Cooperation in Pharmaceutical and HealthcareThe two parties…
-
Coherent Biopharma and C-Ray Therapeutics Partner to Advance Peptide-Drug Conjugate Development
•
China-based Coherent Biopharma and C-Ray Therapeutics have announced a strategic partnership to delve into the development of peptide-drug conjugates (PDCs), with a particular focus on bispecific-ligand drug conjugates (bi-XDCs). The collaboration aims to leverage the strengths of both companies to advance in this innovative field of drug development. Financial details…
-
CANbridge Pharmaceuticals Reports Positive Phase Ib Results for Omoprubart in PNH Treatment
•
China-based rare disease firm CANbridge Pharmaceuticals Inc., (HKG: 1228) has published the preliminary results of a Phase Ib clinical study for its pipeline drug candidate omoprubart (CAN106), a long-acting monoclonal antibody (mAb) targeting C5 of the complement system. The drug candidate is under development as a potential treatment for paroxysmal…
-
Sino Medical Sciences Technology Secures FDA Thailand Approval for NC Rockstar Balloon Catheter
•
China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced that it has received market approval from the Food and Drug Administration of Thailand for its NC Rockstar noncompliant balloon catheter. This development marks a significant step for the company’s expansion into the Southeast Asian medical device market. Product Composition…
